Home > Riviste > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Fascicoli precedenti > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5):158-65

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5):158-65

DOI: 10.23736/S0393-3660.19.04196-2

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

The role of colchicine in preventing contrast-induced acute kidney injury in patients undergoing elective percutaneous coronary intervention

Veysel OKTAY , Ilknur C. CIRALI, Mert SARILAR, Khayel MIRZAYEV, Urfan JAFAROV, Okay ABACI

Department of Cardiology, Institute of Cardiology, Istanbul University-Cerrahpasa, Istanbul, Turkey



BACKGROUND: Contrast induced acute kidney injury (CI-AKI) is a serious complication of percutaneous coronary interventions (PCI) and is associated with increased morbidity and mortality. The aim of this study was to investigate the preventive role of colchicine on CI-AKI in patients undergoing elective PCI considering to its anti-inflammatory and renoprotective effects.
METHODS: This study was designed as a single-centered, randomized, and open-label study including 280 patients undergoing elective PCI with an estimated glomerular filtration rate (eGFR) of >45 mL/min/1.73 m2. One-hundred-forty patients were randomized to the colchicine treatment group (mean age, 60±9 years), whereas 140 patients were randomized to the control group (mean age, 61±7 years). CI-AKI was defined as either a 50% relative increase in serum creatinine levels from the baseline or a 0.3 mg/dL increase in the absolute value that measured 48 h after PCI. Colchicine treatment was started 24 hours before the PCI and continued 48 hours after PCI. Logistic regression analysis was performed to identify the independent predictors of CI-AKI.
RESULTS: CI-AKI occurred in 6 of the 140 patients (4%) in the colchicine group and in 13 of the 140 patients (9%) in the control group (odds ratio [OR]: 0.42; 95% confidence interval [CI]: 0.20 to 0.82; P=0.02). In patients under colchicine treatment, the rate of eGFR reduction after PCI was significantly lower than in that in those not under colchicine treatment (69±13 vs. 66±15, P=0.227; 72±11 vs. 63±13 P<0.001). In logistic regression analysis, age (OR=1.3, 95% CI: 1.1-1.6, P=0.005), diabetes mellitus (OR=2.24 95% CI: 1.17-3.31, P<0.001) and colchicine treatment (OR=0.84, 95% CI: 0.72-0.98, P=0.020) were independent predictors of CI-AKI.
CONCLUSIONS: Prophylactic oral administration of colchicine may protect against CI-AKI in patients undergoing elective PCI with mildly or moderately decreased eGFR values.


KEY WORDS: Acute kidney injury; Colchicine; Percutaneous coronary intervention

inizio pagina